143 related articles for article (PubMed ID: 6788660)
1. A blood component program for the treatment of surgical haemorrhage and its potential for national supplies of albumin and factor VIII.
Lundsgaard-Hansen P
Haematologia (Budap); 1980; 13(1-4):155-67. PubMed ID: 6788660
[TBL] [Abstract][Full Text] [Related]
2. [Experience with a blood component program in surgical hemotherapy].
Lundsgaard-Hansen P
Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(6):933-42. PubMed ID: 6187647
[TBL] [Abstract][Full Text] [Related]
3. [Component therapy of surgical hemorrhage and its significance for the national supply of transfusion commodities (author's transl)].
Lundsgaard-Hansen P
Schweiz Rundsch Med Prax; 1979 Jun; 68(24):755-60. PubMed ID: 450884
[No Abstract] [Full Text] [Related]
4. Component therapy of surgical hemorrhage: red cells, plasma substitutes and albumin.
Lundsgaard-Hansen P; Pappova E
Ann Clin Res; 1981; 13 Suppl 33():26-38. PubMed ID: 7342841
[No Abstract] [Full Text] [Related]
5. [Treatment with blood and blood plasma fractions].
Weise W
Dtsch Med J; 1967 Feb; 18(3):63-6. PubMed ID: 4174358
[No Abstract] [Full Text] [Related]
6. Current transfusion practices.
Pierce LE; Beall CL
Am Fam Physician; 1975 Mar; 11(3):129-36. PubMed ID: 1114933
[TBL] [Abstract][Full Text] [Related]
7. [Use of albumin in surgery].
Guseĭnov ChS; Perova SA; Petrova ET; Tsatsanidi KN; Menteshashvili SM
Vestn Khir Im I I Grek; 1970 Nov; 105(11):82-7. PubMed ID: 5502250
[No Abstract] [Full Text] [Related]
8. Red cells and gelatin as the core of a unified program for the national procurement of blood components and derivatives. Prediction, performance, and impact on supply of albumin and factor VIII.
Lundsgaard-Hansen P; Bucher U; Tschirren B; Haase S; Kuske B; Lüdi H; Stankiewicz LA; Hässig A
Vox Sang; 1978; 34(5):261-75. PubMed ID: 629044
[TBL] [Abstract][Full Text] [Related]
9. [Blood component transfusion in Croatia].
Grgicević D; Bozović I; Pende B
Bilt Hematol Transfuz; 1978; 6(3):13-29. PubMed ID: 757666
[TBL] [Abstract][Full Text] [Related]
10. When should we use blood or blood components?
Knouse CA
J Am Osteopath Assoc; 1977 Apr; 76(8):633, 635-9 concl. PubMed ID: 408391
[No Abstract] [Full Text] [Related]
11. Can a national all voluntary blood transfusion service by adequate blood component therapy cover actual and future needs of albumin?
Barker LF; Cazal P; Haussman HG; Hollán S; Kellner A; Lundsgaard-Hansen P; Schiff P
Vox Sang; 1976; 31?-73(3):225-38. PubMed ID: 969394
[No Abstract] [Full Text] [Related]
12. Impact of the protein content of red cell concentrates on the optimum use of blood.
Lundsgaard-Hansen P
Vox Sang; 1979; 37(2):65-72. PubMed ID: 494583
[TBL] [Abstract][Full Text] [Related]
13. [Production of factor VIII preparations and their use in the substitution therapy of hemophilia A].
Gaerisch F; Stein P
Z Gesamte Inn Med; 1982 Oct; 37(19):641-4. PubMed ID: 6817530
[TBL] [Abstract][Full Text] [Related]
14. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
Brinkhous KM
Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
[TBL] [Abstract][Full Text] [Related]
16. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors.
Lozier JN; Santagostino E; Kasper CK; Teitel JM; Hay CR
Semin Hematol; 1993 Apr; 30(2 Suppl 1):10-21. PubMed ID: 8480192
[TBL] [Abstract][Full Text] [Related]
17. Rationale and indications for continuous infusion of antihemophilic factor (factor VIII).
Goldsmith JC
Blood Coagul Fibrinolysis; 1996 Mar; 7 Suppl 1():S3-6. PubMed ID: 8735789
[TBL] [Abstract][Full Text] [Related]
18. Plasma fractionation in blood transfusion service.
Haskó F; Salamon M; Bartha K; Dobó P
Dev Biol Stand; 1987; 67():39-48. PubMed ID: 3111912
[TBL] [Abstract][Full Text] [Related]
19. [Component therapy with cryo-poor plasma (CPP)].
Roewer J; Dettmann C
Beitr Infusionsther; 1990; 26():168-73. PubMed ID: 1703822
[TBL] [Abstract][Full Text] [Related]
20. Purification and clinical evaluation of a factor 8 concentrate.
Johnson AJ; Karpatkin MH; Newman J
Bibl Haematol; 1970; 34():30-9. PubMed ID: 5436351
[No Abstract] [Full Text] [Related]
[Next] [New Search]
